Fireside Chat, Interview
Shifting Risk Mindsets, from Tech to Bio
- Communication Barriers: Entrepreneurs often fail to translate novel technologies into language that resonates with biological partners and media accustomed to traditional methods.
- Technical founders frequently lack experience with both the tech side of business and the specific "language" of the biospace.
- The "Death by a Thousand Pilots" Trap: Startups often rely on numerous small pilot deals to generate cash, which creates operational inefficiencies.
- Pilots typically offer low upfront payments, requiring a high volume of deals to secure sufficient runway.
- Large corporate partners often induce scope creep and timeline delays, frequently resulting in payment delays (e.g., paying X in 2X time).
- Companies often start as service providers selling pilots to pharma but fail to generate sustainable economics before needing to pivot.
- Value Chain Positioning: Capturing value depends heavily on the specific stage of the drug development pipeline a platform targets.
- Identifying novel targets offers limited value capture because pharma companies are saturated with targets and often view them as "free."
- Platforms that can predict Phase III trial failures offer higher value capture due to the significant cost savings they provide.
- Founders face a dangerous transition when moving from platform developers to drug developers without prior drug design expertise.
- Partnership Strategy: Selecting partners for pilots is critical to avoiding resource drain.
- Founders should only partner with entities that fundamentally believe in the technology and the value of the proof point.
- Effective business development teams act as a strategic advantage by structuring deals that bridge the gap between early-stage validation and downstream value.
- Deal structures must avoid fully encumbering the platform to ensure future flexibility for internal asset development or other partnerships.
- Asset vs. Platform Risk: A single successful asset validates the platform, but resources often shift entirely to that asset, starving the underlying platform.
- Legal structures like LLCs can isolate specific drug assets under separate entities while a "parent" company retains ownership of the broader platform.
- Investors can be segmented into those betting on a single asset and those betting on the long-term productivity of the platform.
- Unvalidated platforms carry existential risk; if the first asset fails, the platform's viability is often questioned regardless of its technical merit.
- Diagnostics Specifics: Reimbursement is the primary risk factor in diagnostics, often preceding regulatory approval concerns.
- Founders should work backwards from reimbursement models and go-to-market strategies rather than focusing solely on clinical trial design.
- Engineering biology to be repeatable across indications allows for targeting markets with the strongest go-to-market potential.
- Reimbursement for early screening is challenging due to patient churn, though self-insured employers and pilots with payers offer potential solutions.
- Innovative financial mechanisms are emerging to address the long-term ROI mismatch for healthcare payers.
- Broad Biology & Instrumentation: Non-therapeutic biology companies face similar proof-of-concept (POC) hurdles but can adopt "tech" strategies.
- Successful models often begin by targeting high-end institutional markets (similar to early sequencing) before opening to broader commercial markets.
- Companies should design a clear path from early adopter POCs to late adopter markets, focusing on variables like throughput, quality, and cost.
- Founders must identify the "killer experiment"—a specific test within 6-12 months that would definitively kill the idea if it fails.
- Funding & Investor Selection: Bio-hybrid companies must navigate different metrics depending on their focus (consumer, enterprise, or therapeutics).
- Traditional bio investors understand science risk, while tech investors focus on growth metrics like DAU/MAU; a hybrid investor syndicate is often necessary.
- Early-stage fundraising should consider the composition of future investor rounds, potentially mixing tech and bio investors to educate each other.
- Companies should define clear metrics to prove progress during the funding period and select investors based on their ability to value those specific metrics.
- Founders must be fluent in one language (tech or bio) and functionally fluent in the other to communicate effectively with diverse investor bases.